Octapharma USA sponsored the National Hemophilia Foundation’s (NHF) 71st Bleeding Disorders Conference and introduced two new clinical trials focused on von Willebrand Disease (VWD). The clinical trials were featured in poster presentations at the NHF meeting held in Anaheim, California last week.
The first study is expected to determine the efficacy and safety of WILATE ® during prophylaxis in previously treated patients with VWD, specifically patients with type 3, type 2 (except 2N), or severe type 1 VWD.
Affecting approximately 1 percent of the population, VWD is a common inherited bleeding disorder that occurs when the blood lacks a protein that helps clotting. Type 3 VWD is the rarest and most severe form of the condition, representing approximately 5% of cases, according to the National Organization for Rare Disorders.
Octapharma USA President Flemming Nielsen stated that “This study is intended to provide data on the efficacy of prophylactic treatment in reducing the rate of bleeding and on the impact of prophylaxis on the quality of life in VWD patients.”
The second clinical trial, von Willebrand Factor in Pregnancy (VIP), is a multicenter study of WILATE use in VWD for childbirth, primarily studying the rate of postpartum hemorrhage and the levels of von Willebrand Factor and FVIII in terms of how high a factor level should be achieved.
WILATE, derived from human plasma, replaces both von Willebrand Factor (VWF) and FVIII proteins that a patient may not have enough of, or that may not work properly to make blood clot. Both factors play important roles in blood clotting.
Octapharma is currently recruiting study sites for both clinical trials. For complete details on the WILATE prophylaxis study, please visit here (ClinicalTrials.gov Identifier: NCT04052698).